Life Science REIT PLC 42.9% potential upside indicated by Berenberg Bank

Life Science REIT PLC with ticker (LON:LABS) now has a potential upside of 42.9% according to Berenberg Bank.

LABS.L

Berenberg Bank set a target price of 57 GBX for the company, which when compared to the Life Science REIT PLC share price of 40 GBX at opening today (21/10/2024) indicates a potential upside of 42.9%. Trading has ranged between 31 (52 week low) and 69 (52 week high) with an average of 1,069,690 shares exchanging hands daily. The market capitalisation at the time of writing is £136,044,649.

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.